Xilio Therapeutics develops tumor-activated immuno-oncology therapies using proprietary platform technology to create targeted molecules that enhance anti-tumor activity within the tumor microenvironment. This approach aims to provide effective treatment options for patients with solid tumors while minimizing systemic side effects associated with traditional immuno-oncology therapies.
Funding
$11.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional immuno-oncology therapies often cause significant systemic side effects, limiting their tolerability and effectiveness in treating solid tumors. These therapies can trigger widespread immune responses, leading to damage in healthy tissues and organs, which restricts the dosage and compromises patient outcomes.
Solution
Xilio Therapeutics is developing tumor-activated immuno-oncology therapies designed to enhance anti-tumor activity specifically within the tumor microenvironment, while minimizing systemic side effects. Their proprietary platform technology creates targeted molecules, including antibodies, cytokines, bispecifics, and cell engagers, that are activated only in the presence of specific tumor markers. This localized activation aims to provide effective treatment options for patients with solid tumors by focusing the immune response directly at the cancer cells, sparing healthy tissues from damage. By optimizing the therapeutic index, Xilio's approach seeks to deliver more tolerable and durable therapeutic benefits.
Target Audience
The primary target audience includes patients with solid tumors who require effective and tolerable immuno-oncology treatment options, as well as oncologists and medical professionals seeking to improve patient outcomes while reducing systemic toxicities.
Features
- Proprietary platform technology for creating tumor-activated immuno-oncology therapies
- Development of targeted molecules, including antibodies, cytokines, bispecifics, and cell engagers
- Molecules are designed to be activated specifically within the tumor microenvironment
- Approach aims to minimize systemic side effects associated with traditional immuno-oncology therapies
- Pipeline of novel, tumor-activated molecules with optimized therapeutic index